Almac Diagnostic Services Join Personalized Medicine Coalition

June 27, 2008

CRAIGAVON, NORTHERN IRELAND, 24th June 2008  – Almac Diagnostic Services today announced it has joined the Personalized Medicine Coalition (PMC).

The Coalition is an independent non-profit group comprised of leading academic, industrial, patient and provider organizations that are dedicated to the advancement, understanding and adoption of personalized medicine. The group provides leadership surrounding the issue and serves as a forum for discussion, education and advocacy.

Professor Paul Harkin, President and Managing Director of Almac Diagnostic Services said:  “At Almac we are committed to the advancement of patient care through translational genomic solutions. We believe we can positively contribute to the progression of personalized medicine through our expertise in biomarker discovery and validation, bioinformatics solutions and genomic services including our proprietary Cancer DSA™ technology.  We are looking forward to working alongside other like-minded organizations and playing a role in the acceleration of personalized medicine and ultimately its benefits to patient care”.

Edward Abrahams, Executive Director of PMC added:  “The PMC is especially pleased that Almac Diagnostic Services has joined its efforts to create a friendlier landscape for the advancement of personalized medicine. The PMC seeks to expand its international focus, and Almac Diagnostic Services is well positioned to contribute to that goal.”

Since its launch in 2004, the coalition has grown to over 140 members, providing a forum for the public, policymakers, government officials and private sector healthcare leaders to further the public interest in personalized medicine and identify policies which will accelerate its adoption. The PMC has engaged with a wide range of organisations, including the FDA, National Human Genome Research Institute and the Center for Medicare and Medicaid Services among others.



Emma O’Neill

Almac Diagnostic Services

T: + 44 (0) 2838 337575

Carl Whyte

Stakeholder Communications

T: + 44 (0) 2890 339949

Notes to Editors

About Almac Diagnostic Services

Almac Diagnostic Services provides translational genomic based solutions for pharma, biotech and academic customers. Almac specialises in working with fresh and formalin fixed paraffin embedded (FFPE) tissue for generation of predictive and prognostic tests, drug development, target identification and companion diagnostics.

About Almac Group

The Almac Group comprises five closely integrated divisions offering a broad range of services from R&D, translational genomic services, API manufacture, formulation development, clinical trial supply and technology (IVRS/Web/EDC), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors. The company has over 2,000 employees and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California. For more information about the Almac Group, please visit

About Personalized Medical Coalition

The Personalized Medicine Coalition, representing a broad spectrum of academic, industrial, patient, provider and payers communities, sees to advance the understanding and adoption of personalized medicine concepts and products for the benefit of patients.

Further information at


Back to news